Back to Search
Start Over
18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.
- Source :
-
PloS one [PLoS One] 2015 Feb 13; Vol. 10 (2), pp. e0115315. Date of Electronic Publication: 2015 Feb 13 (Print Publication: 2015). - Publication Year :
- 2015
-
Abstract
- Background: Conflicting data exist for anti-cancer effects of anti-placental growth factor (anti-PlGF) in combination with anti-VEGF. Still, this treatment combination has not been evaluated in intracranial glioblastoma (GBM) xenografts. In clinical studies, position emission tomography (PET) using the radiolabeled amino acid O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) and magnetic resonance imaging (MRI) add complementary but distinct information about glioma growth; however, the value of 18F-FET MicroPET combined with MicroMRI has not been investigated preclinically. Here we examined the use of 18F-FET MicroPET and MicroMRI for evaluation of anti-VEGF and anti-PlGF treatment response in GBM xenografts.<br />Methods: Mice with intracranial GBM were treated with anti-VEGF, anti-PlGF + anti-VEGF or saline. Bioluminescence imaging (BLI), 18F-FET MicroPET and T2-weighted (T2w)-MRI were used to follow tumour development. Primary end-point was survival, and tumours were subsequently analysed for Ki67 proliferation index and micro-vessel density (MVD). Further, PlGF and VEGFR-1 expression were examined in a subset of the xenograft tumours and in 13 GBM patient tumours.<br />Results: Anti-VEGF monotherapy increased survival and decreased 18F-FET uptake, BLI and MVD, while no additive effect of anti-PlGF was observed. 18F-FET SUV max tumour-to-brain (T/B) ratio was significantly lower after one week (114 ± 6%, n = 11 vs. 143 ± 8%, n = 13; p = 0.02) and two weeks of treatment (116 ± 12%, n = 8 vs. 190 ± 24%, n = 5; p = 0.02) in the anti-VEGF group as compared with the control group. In contrast, T2w-MRI volume was unaffected by anti-VEGF. Gene expression of PlGF and VEGFR-1 in xenografts was significantly lower than in patient tumours.<br />Conclusion: 18F-FET PET was feasible for anti-angiogenic response evaluation and superior to T2w-MRI; however, no additive anti-cancer effect of anti-PlGF and anti-VEGF was observed. Thus, this study supports use of 18F-FET PET for response evaluation in future studies.
- Subjects :
- Animals
Antineoplastic Agents therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Brain Neoplasms diagnosis
Brain Neoplasms genetics
Brain Neoplasms pathology
Cell Line, Tumor
Cell Transformation, Neoplastic
Drug Synergism
Female
Gene Expression Regulation, Neoplastic drug effects
Glioblastoma diagnosis
Glioblastoma genetics
Glioblastoma pathology
Humans
Magnetic Resonance Imaging
Membrane Proteins genetics
Mice
Microvessels drug effects
Optical Imaging
Positron-Emission Tomography
RNA, Messenger genetics
RNA, Messenger metabolism
Survival Analysis
Tomography, X-Ray Computed
Treatment Outcome
Vascular Endothelial Growth Factor Receptor-1 genetics
Antineoplastic Agents pharmacology
Brain Neoplasms drug therapy
Glioblastoma drug therapy
Membrane Proteins antagonists & inhibitors
Multimodal Imaging
Tyrosine analogs & derivatives
Vascular Endothelial Growth Factor A antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 10
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 25680186
- Full Text :
- https://doi.org/10.1371/journal.pone.0115315